NASDAQ:CNTX

Context Therapeutics Q3 2025 Earnings Results & Report

Context Therapeutics logo
$0.17 0.00 (-2.69%)
Closing price 04:00 PM Eastern
Extended Trading
$0.17 +0.00 (+0.96%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Context Therapeutics missed analyst earnings expectations in its Q3 2025 results, released November 5, 2025. The company reported EPS of -$0.10 versus the -$0.09 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Context Therapeutics EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.09
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Context Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Context Therapeutics Q3 2025 Earnings FAQ

Context Therapeutics (NASDAQ:CNTX) reported earnings of -$0.10 per share for Q3 2025, missing the consensus estimate of -$0.09. The report was announced on Wednesday, November 5, 2025.

Context Therapeutics Earnings Headlines

Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
See More Context Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email.

About Context Therapeutics

Context Therapeutics (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company developing treatments for solid tumors. The company’s research focuses on bispecific antibodies designed to direct immune cells toward cancer cells.

Its pipeline includes CTIM-76, a T-cell-engaging bispecific antibody targeting claudin 6, a protein found on certain tumor cells. Context has also been developing CT-95, which targets mesothelin, another protein expressed by some solid tumors.

Founded with an initial focus on therapies for women’s cancers, Context has since broadened its work to address a range of solid tumors. The company is based in the United States and conducts clinical-stage drug development.

View Context Therapeutics Profile